• MobiDrop

  Participated · Series A · Jul 2022

  墨卓生物 provides precision diagnostic and life-science research services built on microfluidic technology. The company is described in the article as China’s first multi-platform new molecular diagnostics company. Its core offering centers on molecular diagnostics and support for life-science research workflows. The article notes a recent financing event but does not disclose operating metrics or revenue. Management is pursuing growth through technology-driven diagnostic platforms and multi-platform molecular testing capabilities. The firm completed a new institutional funding round in late 2023 to support its development and operations. MobiDrop is a biotechnology startup founded in 2018 and based in Zhejiang Province that develops microfluidic and single-cell sequencing technologies. It has built two product lines—single cell sequencing and digital PCR—and developed core technologies in microfluidics, sequencing, biochemistry, hardware development and biotechnology. The company is advancing multiple pipelines including single cell transcriptome products and has more than 15 projects in progress. Its MobiMicrobe™ platform is described as a unique high-throughput microbial single-cell genomics platform, and a key commercial product is the MobiNova-100 high-throughput single cell transcriptome solution (library construction system, reagents and chips, and bioanalysis software). The firm plans to use recent funding to expand its single-cell product R&D pipeline, advance global R&D and promotion of MobiMicrobe™, and promote R&D, production, commercialization and market development. MobiDrop says it aims to accelerate the creation of a diversified and efficient single-cell ecosystem.

No current team members are available.